Biochem Pharma (BCHE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steven Yang who wrote (391)	9/19/1998 12:01:00 PM
From: Steven Yang	Read Replies (1) of 783

BCHE Investors: DuPont's Sustiva was approved by FDA yesterday. The drug is to be used in combination with other drugs. The FDA did not specify which drug(s) are to be used in the combination therapy. However, if one recalls the presentations made during the World AIDS Conference in Summer this year and the associated press reports on Sustiva, the most effective treatment is the combination of Sustiva + Combivir (3TC + AZT). With this treatment, patients will take 3 pills a day instead of up to 15 pills a day, pills are taken twice a day vs. three times a day; pills can be taken with or without food. In addition, the side effect profile seems to be better. Given these advantages, this new treatment method can potentially become a new standard of treatment, particularly for those HIV positive people who have not taken any treatment. Contrary to the bears' case saying Sustiva could replace 3TC, the FDA approval is a positive news for BCHE. Either in the current three drug combination treatment or this newly approved treatment, the cornerstone position of 3TC remains unchallenged. Steven ps: Lamivudine has been approved in the Phillipines. Can the approvals in other East Asia countries be far behind?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next